Pharma companies seek stability in Trump's fight against high drug cost

Several major pharmaceutical companies lowered their spending on lobbyists in the second quarter of 2018, a time of uncertainty as President Donald Trump’s administration continued its campaign to lower drug costs for consumers.
 

Pharmaceutical Research and Manufacturers of America spent $5.54 million between April and June, down 7.7 percent from the same period last year, according to disclosures released by the federal government on Friday.
 

Companies including Johnson & Johnson and Bayer Corp. decreased their spending from the first quarter, when several companies set lobbying records amid the first signs of Trump’s moves to reduce out-of-pocket medicine costs.